Disulfiram-Copper Potentiates Anticancer Efficacy of Standard Chemotherapy Drugs in Bladder Cancer Animal Model through ROS-Autophagy-Ferroptosis Signalling Cascade
Abstract
Background: Cost-effective management of Urinary Bladder Cancer (UBC) is an unmet need Aims: Our study aims to demonstrate the efficacy of a drug repurposing strategy by using disulfiram (DSF) and copper gluconate (Cu) as an add-on treatment combination to traditional GC-based chemother-apy against N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)-induced UBC mice (C57J) model. Methods: Male C57BL/6J mice were given 0.05% BBN in drinking water ad libitum, and tumour for-mation was verified by histological and physical evaluation. Animals were subsequently divided into eight groups and received treatment with different drug combinations. Control animals received only ve-hicle (DMSO). At the end of the treatment schedule, the bladder tumour was excised and further used to check the expression (mRNA and protein) of ALDH1 isoenzymes using qRT-PCR, western blot, and IHC methods. Autophagy induction was assessed by quantifying the expression of LC3B and SQSTM1/p62 proteins through IHC. Biochemical analysis of superoxide dismutase (SOD), reduced glutathione (GSH), and lipid peroxidation levels in the freshly isolated tumours was performed to check the alterations in the antioxidant system caused by combination treatment. Results: We observed significant induction of an invasive form of bladder cancer in the mice after nine-teen weeks of BBN exposure. The animals began exhibiting early indications of inflammatory alterations as early as the sixth week following BBN treatment. Furthermore, the wet bladder weight and overall tu-mour burden were significantly decreased (p< 0.0001) by DSF-Cu co-treatment in addition to the GC-based chemotherapy. Real-time PCR analysis revealed that treatment with disulfiram and copper glu-conate significantly decreased (p<0.0001) the mRNA expression of ALDH1 isoenzymes. Comparing the triple drug combination group (GC+DSF-Cu) to the untreated mice, a significant rise in LC3B puncta (p<0.0001) and a decrease in P62/SQSTM1 (p=0.0002) were noted, indicating the induction of autophagy flux in the add-on group. When GC+DSF-Cu treated mice were compared to the untreated tumour group, a substantial decrease in ALDH1/2 protein expression was observed (p= 0.0029 in IHC and p<0.0001 in western blot). Lipid peroxidation was significantly higher (p<0.0001) in the triple drug combination group than in untreated mice. There was a simultaneous decrease in reduced glutathione (GSH) and en-zyme superoxide dismutase (SOD) levels (p<0.0001), which strongly suggests the generation of reactive oxygen species and induction of ferroptotic cell death in the add-on therapy group. Additionally, in both IHC and western blot assays, ALDH1A3 expression was found to be significantly increased (p=0.0033, <0.0001 respectively) in GC+DSF-Cu treated mice relative to the untreated group, suggesting a potential connection between the ferroptosis pathway and ALDH1A3 overexpression. Conclusion: It was found that disulfiram with copper treatment inhibits bladder tumour growth through ferroptosis-mediated ROS induction, which further activates the process of autophagy. Our results prove that DSF-Cu can be an effective add-on therapy along with the standard chemotherapy drugs for the treatment of UBC.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Several mechanisms have been reported for the induction of apoptosis by disulfiram in cancer cells, including inhibition of proteasome activity, regulation of transcription factors (e.g., NF-κB), activation of JNK signaling, and activation of the mitochondria-related intrinsic apoptotic pathway.
“In addition to ROS generation,58 several mechanisms have been reported for the induction of apoptosis by DIS in cancer cells, including the inhibition of proteasome activity,59,60 regulation of transcription factors [e.g., nuclear factor-kappa B (NF-κB)],61,62,63,64 activation of the stress-related c-Jun N-terminal kinases (JNK) signaling pathway65,66 and activation of the mitochondria-related”
From Off-label and repurposed use of disulfiram beyond alcohol dependence: A systematic review of clinical and preclinical evidence (2026) · cites this paper as [58]
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860 · see citing works
Tietze, F. (1969) · Analytical Biochemistry · doi:10.1016/0003-2697(69)90064-5 · Cited by 6,077 · see citing works
Pankiv, S., Clausen, T. H., Lamark, T., Brech, A., Bruun, J.-A., Outzen, H., Øvervatn, A., Bjørkøy, G., & Johansen, T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702824200 · Cited by 4,578 · see citing works
Epidemiology of Bladder Cancer
Saginala, K., Barsouk, A. A., Aluru, J. S., Rawla, P., Padala, S. A., & Barsouk, A. (2020) · Medical Sciences · doi:10.3390/medsci8010015 · Cited by 926 · see citing works
Şanlı, Ö., Dobruch, J. T., Knowles, M. A., Burger, M., Mehrdad Alemozaffar, A., Nielsen, M. E., & Lotan, Y. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.22 · Cited by 819 · see citing works
Characteristics and Biomarkers of Ferroptosis
Chen, X., Comish, P. B., Tang, D., & Kang, R. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.637162 · Cited by 516 · see citing works
Reaction of linoleic acid hydroperoxide with thiobarbituric acid.
Ohkawa, H., Ohishi, N., & Yagi, K. (1978) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)40690-x · Cited by 450 · see citing works
Identification of essential sites of lipid peroxidation in ferroptosis
von Krusenstiern, A. N., Robson, R. N., Qian, N., Qiu, B., Hu, F., Reznik, E., Smith, N., Zandkarimi, F., Estes, V. M., Dupont, M. M., et al. (2023) · Nature Chemical Biology · doi:10.1038/s41589-022-01249-3 · Cited by 425 · see citing works
Anderson, D. J., Moigne, R. L., Djakovic, S. N., Kumar, B., Rice, J., Wong, S., Wang, J., Yao, B., Valle, E., Soly, S. K. V., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.002 · Cited by 391 · see citing works
Durak, İ., Yurtarslanl, Z., Canbolat, O., & Akyol, Ö. (1993) · Clinica Chimica Acta · doi:10.1016/0009-8981(93)90307-p · Cited by 388 · see citing works
Ren, X., Li, Y., Zhou, Y., Hu, W., Yang, C., Jing, Q., Zhou, C., Wang, X., Hu, J., Wang, L., et al. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102122 · Cited by 313 · see citing works
The role of mouse tumour models in the discovery and development of anticancer drugs
Ireson, C. R., Alavijeh, M. S., Palmer, A. M., Fowler, E. R., & Jones, H. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0495-5 · Cited by 219 · see citing works
Methods for the Determination of Plasma or Tissue Glutathione Levels
Tipple, T. E., & Rogers, L. K. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-867-2_20 · Cited by 160 · see citing works
Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives
Wołącewicz, M., Hrynkiewicz, R., Grywalska, E., Suchojad, T., Leksowski, T., Roliński, J., & Niedźwiedzka‐Rystwej, P. (2020) · Cancers · doi:10.3390/cancers12051181 · Cited by 149 · see citing works
Lu, Y., Pan, Q., Gao, W., Pu, Y., Luo, K., He, B., & Gu, Z. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2021.121335 · Cited by 149 · see citing works
Cisplatin Mouse Models: Treatment, Toxicity and Translatability
Perše, M. (2021) · Biomedicines · doi:10.3390/biomedicines9101406 · Cited by 141 · see citing works
Kannappan, V., Ali, M., Small, B., Rajendran, G., Elzhenni, S., Taj, H., Wang, W., & Dou, Q. P. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.741316 · Cited by 134 · see citing works
Cheng, Y., Song, Y., Chen, H., Li, Q., Gao, Y. Z., Lu, G., & Luo, C. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/5005136 · Cited by 122 · see citing works
Use of C57BL/6N mice on the variety of immunological researches
Song, H. K., & Hwang, D. Y. (2017) · Laboratory Animal Research · doi:10.5625/lar.2017.33.2.119 · Cited by 87 · see citing works
Wu, W. E., Wu, Y., Mayer, K., von Rosenstiel, C., Schecker, J., Baur, S., Würstle, S. M., Liesche‐Starnecker, F., Gempt, J., & Schlegel, J. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100748 · Cited by 71 · see citing works
Development and progression of urothelial carcinoma
Kakizoe, T. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00264.x · Cited by 66 · see citing works
The Disulfiram/Copper Complex Induces Autophagic Cell Death in Colorectal Cancer by Targeting ULK1
Hu, Y., Qian, Y., Wei, J., Jin, T., Kong, X., Cao, H., & Ding, K. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.752825 · Cited by 63 · see citing works
Qiu, C., Zhang, X., Huang, B., Wang, S., Zhou, W., Li, C., Li, X., Wang, J., & Yang, N. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s272312 · Cited by 60 · see citing works
Management of Muscle-invasive Bladder Cancer in the 2020s: Challenges and Perspectives
Gakis, G. (2020) · European Urology Focus · doi:10.1016/j.euf.2020.01.007 · Cited by 59 · see citing works
The dynamics of the inflammatory response during BBN-induced bladder carcinogenesis in mice
Degoricija, M., Korać-Prlić, J., Vilović, K., Ivanišević, T., Haupt, B. E., Palada, V., Petković, M., Karaman, I., & Terzić, J. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-02146-5 · Cited by 50 · see citing works
Nie, D., Chen, C., Li, Y., & Zeng, C. (2022) · Blood Science · doi:10.1097/bs9.0000000000000117 · Cited by 46 · see citing works
Majera, D., Skrott, Z., Chroma, K., Merchut-Maya, J. M., Mistrik, M., & Bartek, J. (2020) · Cells · doi:10.3390/cells9020469 · Cited by 43 · see citing works
Drug Repurposing for Cancer Therapy in the Era of Precision Medicine
To, K. K. W., & Cho, W. C. S. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220214104530 · Cited by 42 · see citing works
Li, C., Zhou, S., Chen, C., Zhu, L., Li, S., Song, Z., Liang, J., Tang, C., Xu, N., Liu, T., et al. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113253 · Cited by 40 · see citing works
Current and Future Landscape of Perioperative Treatment for Muscle-Invasive Bladder Cancer
Esteban-Villarrubia, J., Torres-Jiménez, J., Bueno-Bravo, C., García-Mondaray, R., Subiela, J. D., & Gajate, P. (2023) · Cancers · doi:10.3390/cancers15030566 · Cited by 30 · see citing works
Current animal models of bladder cancer: Awareness of translatability (Review)
Ding, J., Xu, D., Pan, C., Ye, M., Kang, J., BAI, Q., & Qi, J. (2014) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2014.1837 · Cited by 30 · see citing works
ALDH1-Mediated Autophagy Sensitizes Glioblastoma Cells to Ferroptosis
Wu, Y., Kram, H., Gempt, J., Liesche‐Starnecker, F., Wu, W. E., & Schlegel, J. (2022) · Cells · doi:10.3390/cells11244015 · Cited by 21 · see citing works
BBN-driven urinary bladder cancer mouse model
Korać-Prlić, J., Degoricija, M., Vilović, K., Vujević, S., & Terzić, J. (2020) · Methods in cell biology · doi:10.1016/bs.mcb.2020.10.020 · Cited by 13 · see citing works
Induction of tumours by administration of N-dibutylnitrosamine and derivatives to infant mice
Fujii, K., Odashima, S., & Okada, M. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.95 · Cited by 11 · see citing works
Pichler, R., Loidl, W. C., & Pichler, M. (2018) · Translational Andrology and Urology · doi:10.21037/tau.2018.08.15 · Cited by 5 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Inducers of Autophagy and Cell Death: Focus on Copper Metabolism
Ling, W., Li, S., Zhu, Y., Wang, X., Jiang, D., & Kang, B. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.117725 · Cited by 37 · see citing works
Boaru, D. L., León-Oliva, D. D., Castro-Martinez, P. D., Montero, C. G., Fraile‐Μartinez, O., García-González, B., Pérez-González, I., Alhaddadin, M. N. M., Barrena-Blázquez, S., López-González, L., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118422 · Cited by 23 · see citing works
Ferroptosis: a novel pharmacological mechanism against multiple myeloma
Shi, J., Lu, Y., Wei, W., Ma, G., Li, C., Li, L., Wang, Y., Wang, Y., Xu, R., & Cui, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1606804 · Cited by 14 · see citing works
Cuproptosis Inducers in Cancer Therapy: State of the Art and Challenges
Ragusa, C., & Oliveri, V. (2026) · The Chemical Record · doi:10.1002/tcr.70179 · Cited by 2 · see citing works
Benkő, B.-M., De Brito Parreirinha, N. S., Sebe, I., & Zelkó, R. (2026) · iScience · doi:10.1016/j.isci.2026.115441 · Cited by 2 · see citing works
Karamanakos, P. N., Fouka, M., Αρέθα, Δ., Panteli, E. S., Panopoulos, I., Kletsas, D., GOUSSIA, A. C., Papoudou‐Bai, A., Zacharioudaki, A., Trafalis, D. T., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041966 · Cited by 1 · see citing works
A multilevel ensemble model for predicting mutation types in bladder cancer
Jain, A., Dey, S., Garg, D., Singh, H., Pattanaik, S., Mavuduru, R. S., & Rana, P. S. (2025) · Personalized Medicine · doi:10.1080/17410541.2025.2592530
Self-citationWang, X. H., Zhao, J., Li, Q., Chang, J., Zhao, W., & Xing, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1783929
Kumari, S., & Rai, S. K. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1908766
- Authors
- Sharma, N., Dey, S., Singh, S., Kumar, S., Konar, M., Naithani, P., Panwar, R., Rastogi, P., Kakkar, A. K., Mavuduru, R. S., & Pattanaik, S.
- Affiliations
- Post Graduate Institute of Medical Education and Research (IN)
- Corresponding author
- Pattanaik, Smita
- ORCID
- Venue
- Current Cancer Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2025-09
- Volume
- 25
- Issue
- 9
- Pages
- 1145-1157
- ISSN
- 1568-0096 (ISSN-L)
- OpenAlex
- W4402891145
- Cited by
- 9
- References
- 35
- Citations by year
- 2026: 5 · 2025: 4
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Cancer Drug Targets (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Postgraduate Institute of Medical Education and Research, Chandigarh, Department of Pharmacology (PGI/MERC/2019/286-90)
- Topics
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Ferroptosis and cancer prognosis
- Health Sciences › Medicine › Epidemiology › Autophagy in Disease and Therapy
- Keywords
- disulfiram, copper gluconate, drug repurposing, bladder cancer, combination chemotherapy, autophagy, ferroptosis, reactive oxygen species, ALDH1, ALDH2, lipid peroxidation, glutathione, superoxide dismutase, LC3B, p62, chemoresistance
- MeSH terms
- Ferroptosis, Organocopper Compounds, Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Autophagy, Urinary Bladder Neoplasms, Butylhydroxybutylnitrosamine, Copper, Disease Models, Animal, Disulfiram, Drug Combinations, Drug Synergism, Humans, Male, Mice, Inbred C57BL, Signal Transduction, Reactive Oxygen Species, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
